Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.

Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, Koutoku H, Sasamata M, Kobori M, Katou M, Tawara S, Kawabata S, Furuichi K.

Biochem Biophys Res Commun. 2012 Sep 7;425(4):711-6. doi: 10.1016/j.bbrc.2012.07.103. Epub 2012 Jul 27.

PMID:
22842455
2.

Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.

Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG, Li F.

Int J Biochem Mol Biol. 2012;3(2):179-97. Epub 2012 May 18.

3.

Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin.

Nakamura N, Yamauchi T, Hiramoto M, Yuri M, Naito M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, Koutoku H, Sasamata M, Yokota H, Kawabata S, Furuichi K.

Mol Cell Proteomics. 2012 Jul;11(7):M111.013243. doi: 10.1074/mcp.M111.013243. Epub 2012 Mar 22.

4.

YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.

Yamanaka K, Nakata M, Kaneko N, Fushiki H, Kita A, Nakahara T, Koutoku H, Sasamata M.

Int J Oncol. 2011 Sep;39(3):569-75. doi: 10.3892/ijo.2011.1077. Epub 2011 Jun 14.

PMID:
21674125
5.

YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.

Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T, Koutoku H, Sasamata M.

Anticancer Drugs. 2011 Jun;22(5):454-62. doi: 10.1097/CAD.0b013e328344ac68.

PMID:
21389848
6.

Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.

Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N, Sasamata M.

Leuk Res. 2011 Jun;35(6):787-92. doi: 10.1016/j.leukres.2010.11.016. Epub 2011 Jan 14.

PMID:
21237508
7.

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.

Iwasa T, Okamoto I, Takezawa K, Yamanaka K, Nakahara T, Kita A, Koutoku H, Sasamata M, Hatashita E, Yamada Y, Kuwata K, Fukuoka M, Nakagawa K.

Br J Cancer. 2010 Jun 29;103(1):36-42. doi: 10.1038/sj.bjc.6605713. Epub 2010 Jun 1.

8.

(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.

Kinoyama I, Taniguchi N, Toyoshima A, Nozawa E, Kamikubo T, Imamura M, Matsuhisa A, Samizu K, Kawanimani E, Niimi T, Hamada N, Koutoku H, Furutani T, Kudoh M, Okada M, Ohta M, Tsukamoto S.

J Med Chem. 2006 Jan 26;49(2):716-26.

PMID:
16420057
9.

A role of androgen receptor protein in cell growth of an androgen-independent prostate cancer cell line.

Furutani T, Takeyama K, Koutoku H, Ito S, Taniguchi N, Suzuki E, Kudoh M, Shibasaki M, Shikama H, Kato S.

Biosci Biotechnol Biochem. 2005 Nov;69(11):2236-9.

10.

Human expanded polyglutamine androgen receptor mutants in neurodegeneration as a novel ligand target.

Furutani T, Takeyama K, Tanabe M, Koutoku H, Ito S, Taniguchi N, Suzuki E, Kudoh M, Shibasaki M, Shikama H, Kato S.

J Pharmacol Exp Ther. 2005 Nov;315(2):545-52. Epub 2005 Aug 3. Retraction in: J Pharmacol Exp Ther. 2014 Mar;348(3):493.

11.

N-Arylpiperazine-1-carboxamide derivatives: a novel series of orally active nonsteroidal androgen receptor antagonists.

Kinoyama I, Taniguchi N, Kawaminami E, Nozawa E, Koutoku H, Furutani T, Kudoh M, Okada M.

Chem Pharm Bull (Tokyo). 2005 Apr;53(4):402-9.

12.

Synthesis and pharmacological evaluation of novel arylpiperazine derivatives as nonsteroidal androgen receptor antagonists.

Kinoyama I, Taniguchi N, Yoden T, Koutoku H, Furutani T, Kudoh M, Okada M.

Chem Pharm Bull (Tokyo). 2004 Nov;52(11):1330-3.

13.

Stabilization of androgen receptor protein is induced by agonist, not by antagonists.

Furutani T, Watanabe T, Tanimoto K, Hashimoto T, Koutoku H, Kudoh M, Shimizu Y, Kato S, Shikama H.

Biochem Biophys Res Commun. 2002 Jun 21;294(4):779-84.

PMID:
12061774
14.

A novel class of inhibitors for human and rat steroid 5alpha-reductases: synthesis and biological evaluation of indoline and aniline derivatives. III.

Igarashi S, Inami H, Hara H, Koutoku H, Oritani H, Mase T.

Chem Pharm Bull (Tokyo). 2000 Nov;48(11):1689-97.

PMID:
11086897
15.

A novel class of inhibitors for human steroid 5alpha-reductase: synthesis and biological evaluation of indole derivatives. II.

Igarashi S, Inami H, Hara H, Fujii M, Koutoku H, Oritani H, Mase T.

Chem Pharm Bull (Tokyo). 2000 Mar;48(3):382-8.

PMID:
10726862
16.

A novel class of inhibitors for human steroid 5 alpha-reductase: phenoxybenzoic acid derivatives. I.

Igarashi S, Kimura T, Naito R, Hara H, Fujii M, Koutoku H, Oritani H, Mase T.

Chem Pharm Bull (Tokyo). 1999 Aug;47(8):1073-80.

PMID:
10478462
17.

Transport and metabolism of glutathione isopropyl ester in cerebrospinal fluid.

Shikama H, Ohta A, Iwai A, Koutoku H, Umeda M, Noguchi K, Takeda M, Ohhata I.

Res Commun Mol Pathol Pharmacol. 1995 Jun;88(3):349-57.

PMID:
8564390
18.

Acid phosphatase in rat liver lysosomal membranes: purification and characterization.

Himeno M, Koutoku H, Ishikawa T, Kato K.

J Biochem. 1989 Mar;105(3):449-56.

19.

Purification and characterization of acid phosphatase in rat liver lysosomal contents.

Himeno M, Koutoku H, Tsuji H, Kato K.

J Biochem. 1988 Nov;104(5):773-6.

Supplemental Content

Loading ...
Support Center